Targeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drugs that have the potential to reach high concentration at the tumour site. Not only do these agents improve remission and overall survival, but also many new studies have shown that they can be even more effective when used in combination with more traditional therapies. This unique book brings together a series of topical discussions of how the new immunotherapeutic agents can be used successfully to treat lymphoid malignancies. The contributors are prestigious clinicians and researchers working at the cutting edge of the field. This will be an invaluable resource for the haematologist or oncologist who will find up-to-date data and clinical advice regarding the latest immunotherapeutic options in haematology.
具體描述
讀後感
評分
評分
評分
評分
用戶評價
相關圖書
本站所有內容均為互聯網搜索引擎提供的公開搜索信息，本站不存儲任何數據與內容，任何內容與數據均與本站無關，如有需要請聯繫相關搜索引擎包括但不限於百度，google,bing,sogou 等
© 2025 qciss.net All Rights Reserved. 小哈圖書下載中心 版权所有